Stifel raised the firm’s price target on Glaukos to $130 from $110 and keeps a Buy rating on the shares. iDose “rightfully remains front-and-center” and will be the primary stock driver, but the firm believes the pipeline outside of iDose innovation is underappreciated and estimates that an additional $1B-plus of ex-iDose pipeline value can potentially be generated by 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: